The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.

@article{Serrano2008TheCC,
  title={The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.},
  author={Antonia Serrano and Ignacio del Arco and Francisco Javier Pav{\'o}n and Manuel Mac{\'i}as and Vidal P{\'e}rez-Valero and Fernando Rodr{\'i}guez de Fonseca},
  journal={Neuropharmacology},
  year={2008},
  volume={54 1},
  pages={226-34}
}
Anandamide and oleoylethanolamide (OEA) are lipid mediators that regulate feeding and lipid metabolism. While anandamide, a cannabinoid CB1 receptor agonist, promotes feeding and lipogenesis, oleoylethanolamide, an endogenous agonist of peroxisome proliferator activated receptor alpha (PPAR-alpha), decreases food intake and activates lipid mobilization and oxidation. The treatment with a cannabinoid CB1 receptor antagonist results in reduction of body weight gain and cholesterol in obese humans… CONTINUE READING
30 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 30 extracted citations

Similar Papers

Loading similar papers…